Are these ASX blue chips now too cheap to ignore?

Let's see why these shares could be seriously undervalued at current levels.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even the highest-quality companies are not immune to market selloffs.

In fact, periods of uncertainty often see investors pull back from even the most established names. While that can be uncomfortable in the short term, it can also create opportunities to buy leading businesses at more attractive prices.

Here are three ASX blue chips that have fallen heavily and could be worth a closer look.

Couple looking at their phone surprised, symbolising a bargain buy.

Image source: Getty Images

Cochlear Ltd (ASX: COH)

The first ASX blue chip that could be too cheap to ignore is Cochlear.

The hearing solutions company recently disappointed the market with a softer-than-expected result, driven in part by a slower rollout of its new Nexa system and margin pressure from product mix.

While this has weighed on sentiment, it does not change Cochlear's long-term position as a global leader in implantable hearing devices.

Demand for hearing solutions continues to grow due to ageing populations and increased awareness. Cochlear also benefits from a large installed base, which generates recurring revenue through upgrades and servicing.

If the company can execute on its product rollout and return to stronger growth, the current weakness could prove temporary.

CSL Ltd (ASX: CSL)

Another ASX blue chip that may be worth considering is CSL.

The biotech giant's shares have fallen sharply following a soft result and the unexpected CEO transition, which has created uncertainty around its near-term outlook.

The key issue has been weaker-than-expected performance in its CSL Behring division, particularly in immunoglobulin, alongside slower margin recovery than the market had anticipated.

However, CSL still operates in global healthcare markets with strong demand and high barriers to entry. Its therapies address serious medical conditions, and long-term growth drivers remain intact.

While challenges remain, the company's track record and market position suggest it has the capability to work through this period and return to more consistent growth.

James Hardie Industries plc (ASX: JHX)

A third ASX blue chip that could be trading at an attractive level is James Hardie Industries.

The building materials company has been under pressure due to concerns about housing market weakness, particularly in the United States.

Slower construction activity can weigh on demand for its fibre cement products, which has led to more cautious sentiment from investors.

However, James Hardie remains a leader in its category, with strong brand recognition and a history of gaining market share over time.

When housing activity eventually recovers, the company could be well placed to benefit. In the meantime, it continues to focus on innovation and expanding its product offering.

For investors willing to look beyond the near-term uncertainty, this could make it an interesting option at current levels.

Motley Fool contributor James Mickleboro has positions in CSL and Cochlear. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Man holding out Australian dollar notes, symbolising dividends.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These large businesses are providing investors a lot of passive income.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Blue Chip Shares

Why I'd put $2,000 into CBA and these blue-chip ASX shares this month

These ASX shares give investors exposure to banking, groceries, logistics, and digital infrastructure.

Read more »

Buy and sell written on a white cube.
Blue Chip Shares

Why these ASX blue-chip shares are strong buys right now

Experts are bullish about what these ASX shares can deliver.

Read more »

A man looking at his laptop and thinking.
Blue Chip Shares

3 ASX shares Warren Buffett would probably love right now

Warren Buffett looks for moats, management quality, and fair prices. Here's three ASX shares that tick every one of his…

Read more »

Photo of two women shopping.
Blue Chip Shares

Why is everyone talking about Wesfarmers shares this week?

The blue-chip giant is hitting headlines this week.

Read more »

Parents putting money in piggy bank for kids' future.
Blue Chip Shares

My 3 best ASX 200 blue-chip shares to buy in June

June could be a good month to look again at high-quality ASX 200 shares with scale, strong brands, and room…

Read more »

Smiling woman looking through a plane window.
Blue Chip Shares

Why brokers are turning bullish on Qantas shares after a strong May performance

Qantas shares fell from their February peak but brokers see significant upside. Here's why the bulls are backing a recovery…

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Blue Chip Shares

Short sellers are targeting these 3 ASX shares this week. Are they right?

Short sellers are targeting WiseTech, Cochlear, and Lendlease shares. Here is whether the bears have a compelling case for each.

Read more »